UPF
19.11.2020 12:54:08 CET | Business Wire | Press release
The Rally of Hope, the third organized by UPF, is expected to draw much international participation this weekend. This rally, produced in Korea, will focus mainly on the Korean peninsula, seventy years after the outbreak of the Korean war (1950-53). UPF is an NGO in general consultative status with the Economic and Social Council of the United Nations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005660/en/
Remembering yesterday’s war heroes; highlighting today’s peacemakers
In addition to featuring prominent global leaders, the renowned Little Angels Folk Ballet of Korea will perform a special tribute in honor of veterans of the Korean War.
Dr. Hak Ja Han Moon , the co-founder of UPF, will be keynote speaker. Her husband, the late Reverend Moon, was liberated by UN forces from the North Korean death camp of Heungnam. In her memoirs, Mother of Peace , Mrs. Moon explains how she escaped death several times during this conflict.
Further speakers include current and former heads of state and government whose countries were part of the United Nations forces in the Korean War: Sahle-Work Zewde , president of Ethiopia, the only current female head of State in Africa; Yves Leterme , Prime Minister of Belgium (2009-2011); Stephen Harper Prime Minister of Canada (2006-2015), now chairman of the International Democrat Union.
Other speakers include current heads of state whose countries have overcome domestic tensions and progressed toward national reconciliation: Salva Kiir , President of South Sudan, who recently invited the UPF chairman to attend the signing of the Juba peace agreement; Uhuru Kenyatta , President of Kenya and Mahinda Rajapaska , Prime Minister of Sri Lanka.
Mr. Jacques Marion , president of UPF Europe-Middle East, remarked that the Rally of Hope sets a strong signal for a peaceful unification. The interfaith prayer by religious leaders, the presence of Veterans of the Korean war representing the conflicting armies, will testify and sound an appeal for reconciliation on the divided peninsula, he said.
UPF states on its website that a main objective is the “peaceful reunification of the Korean peninsula and harmonious relations among the nations of Northeast Asia.” Directed towards this goal, UPF strives to realize the vision of a global democratic society, driven by the free-market and centered on family-based universal values.
This rally will be a dazzling display of digital technology from the land of K‑pop. A live internet audience of millions will be joined by an interactive audience using various social media apps.
Rally of Hope - Live Broadcast:
Date: November 22, 2020, 1:30 AM - 3:30 AM CET
Participants: VIPs & guests from all over the world (register at: rallyofhope.eu
)
Highlights of the Rally (Online):
November 22, 2020, 6:00 PM - 7:00 PM CET
Participants: VIPs & guests from all over Europe & Middle East
Public registration for the rally (live or highlights) at: rallyofhope.eu
Media direct live streaming will use: peacelink.live
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005660/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom